Due to dose-limiting toxicities of NVP-BGT226 in clinical trials [32], we tested additional PI3K/mTOR inhibitors for their efficacy in the TFE3-fusion RCC cell lines and found that LY3023414 demonstrated an IC50 of 325-740nM in 2D studies and 622nM-3.25μM in 3D spheroid models (Supplementary Figure S2). The gene discussed is MTOR; the disease is renal cell carcinoma.